Xerostomia (Dry Mouth Disease) Therapeutics Market

Executive Summary

Xerostomia (Dry Mouth Disease) Therapeutics Market was valued at US $712.79 million in 2021 and is projected to grow at 4.29% CAGR over the forecast period to reach US $917.25 million by 2027. Xerostomia (Dry Mouth Disease) Therapeutics Market represented US $57.47 million opportunity over 2019-2021 and estimated to create US $204.46 million opportunity in 2027 over 2021.

Xerostomia (Dry Mouth Disease) Therapeutics from Consainsights analyses the Xerostomia (Dry Mouth Disease) Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Xerostomia (Dry Mouth Disease) Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Xerostomia (Dry Mouth Disease) Therapeutics segmentation includes Type, Product, Distribution Channel and Geography.

Based on the Type, the Xerostomia (Dry Mouth Disease) Therapeutics analysis covers Artificial Saliva/Saliva Substitutes, Salivary Stimulants.

In Type segment, Artificial Saliva/Saliva Substitutes segment has highest cagr growth of 3.81%.

Based on the Product, the Xerostomia (Dry Mouth Disease) Therapeutics analysis covers Drugs, Salivary Pens, Other Product Types.

In Product segment, Drugs segment has highest cagr growth of 3.81%.

Based on the Distribution Channel, the Xerostomia (Dry Mouth Disease) Therapeutics analysis covers Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

In Distribution Channel segment, Hospital Pharmacy segment has highest cagr growth of 3.81%.

Based on the region, the Xerostomia (Dry Mouth Disease) Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Quest Products Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Limited, Pharmascience Inc (Pendopharm), Parnell Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd, Synedgen Inc. (Prisyna), ADVANZ PHARMA Corp. Limited, Saliwell Ltd, 3M company and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Salivary Stimulants segment has the highest revenue of US $392.41 million and is expected to grow at CAGR of 3.81% by 2027 Artificial Saliva/Saliva Substitutes segment has highest cagr growth of 3.81%.

Artificial Saliva/Saliva Substitutes

Artificial Saliva/Saliva Substitutes segment was valued at US $294.55 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $412.28 million by 2027. Artificial Saliva/Saliva Substitutes segment represented US $25.83 million opportunity over 2019-2021 and estimated to create US $91.90 million opportunity in 2027 over 2021.

Salivary Stimulants

Salivary Stimulants segment was valued at US $360.77 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $504.97 million by 2027. Salivary Stimulants segment represented US $31.64 million opportunity over 2019-2021 and estimated to create US $112.56 million opportunity in 2027 over 2021.

Product

Introduction

In 2021, Drugs segment has the highest revenue of US $303.42 million and is expected to grow at CAGR of 3.81% by 2027 Drugs segment has highest cagr growth of 3.81%.

Drugs

Drugs segment was valued at US $278.95 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $390.45 million by 2027. Drugs segment represented US $24.46 million opportunity over 2019-2021 and estimated to create US $87.04 million opportunity in 2027 over 2021.

Salivary Pens

Salivary Pens segment was valued at US $223.72 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $313.14 million by 2027. Salivary Pens segment represented US $19.62 million opportunity over 2019-2021 and estimated to create US $69.80 million opportunity in 2027 over 2021.

Other Product Types

Other Product Types segment was valued at US $152.65 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $213.66 million by 2027. Other Product Types segment represented US $13.39 million opportunity over 2019-2021 and estimated to create US $47.63 million opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacy segment has the highest revenue of US $432.16 million and is expected to grow at CAGR of 3.81% by 2027 Hospital Pharmacy segment has highest cagr growth of 3.81%.

Hospital Pharmacy

Hospital Pharmacy segment was valued at US $397.32 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $556.13 million by 2027. Hospital Pharmacy segment represented US $34.84 million opportunity over 2019-2021 and estimated to create US $123.97 million opportunity in 2027 over 2021.

Retail Pharmacy

Retail Pharmacy segment was valued at US $229.15 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $320.75 million by 2027. Retail Pharmacy segment represented US $20.10 million opportunity over 2019-2021 and estimated to create US $71.50 million opportunity in 2027 over 2021.

Online Pharmacy

Online Pharmacy segment was valued at US $28.85 million in 2019 and is projected to grow at 3.81% CAGR over the forecast period to reach US $40.38 million by 2027. Online Pharmacy segment represented US $2.53 million opportunity over 2019-2021 and estimated to create US $9.00 million opportunity in 2027 over 2021.